Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2008 Nov;57(11):2977–2991. doi: 10.2337/db08-0161

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2008, American Diabetes Association

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

PMC Copyright notice

FIG. 6. — Effect of CB1 antagonism in the regulation of insulin action and hepatic glucose production in DIO rats. A: Schematic representation of the euglycemic-hyperinsulinemic clamps. B: Effect of a 6-day intracerebroventricular (icv) CB1 antagonist (5 μg/day) infusion on GIR in DIO rats. C: Effect of a 6-day intracerebroventricular CB1 antagonist (5 μg/day) infusion on hepatic glucose production (HPG) in DIO rats. D: Effect of a 6-day intraperitoneal (ip) CB1 antagonist (10 mg/kg) administration on GIR in DIO rats. E: Effect of a 6-day intraperitoneal CB1 antagonist (10 mg/kg) administration on hepatic glucose production (HPG) in DIO rats. F: Effect of a 6-day intraperitoneal CB1 antagonist (10 mg/kg) administration on liver mRNA expression of glucose 6 phosphatase in DIO rats. Values are means ± SE of five to seven animals per group. *P < 0.05. B–F: □, vehicle; ▪, CB1 antagonist;, vehicle-pf.

Inline graphic — Effect of CB1 antagonism in the regulation of insulin action and hepatic glucose production in DIO rats. A: Schematic representation of the euglycemic-hyperinsulinemic clamps. B: Effect of a 6-day intracerebroventricular (icv) CB1 antagonist (5 μg/day) infusion on GIR in DIO rats. C: Effect of a 6-day intracerebroventricular CB1 antagonist (5 μg/day) infusion on hepatic glucose production (HPG) in DIO rats. D: Effect of a 6-day intraperitoneal (ip) CB1 antagonist (10 mg/kg) administration on GIR in DIO rats. E: Effect of a 6-day intraperitoneal CB1 antagonist (10 mg/kg) administration on hepatic glucose production (HPG) in DIO rats. F: Effect of a 6-day intraperitoneal CB1 antagonist (10 mg/kg) administration on liver mRNA expression of glucose 6 phosphatase in DIO rats. Values are means ± SE of five to seven animals per group. *P < 0.05. B–F: □, vehicle; ▪, CB1 antagonist;, vehicle-pf.